MedTrace Logo

Ketamine for Postoperative Pain in Bariatric Surgery

NCT03389022 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2021-11-22

No results posted yet for this study

Summary

The aim of this study was to evaluate an effect of pre - incisional single injection of low-dose ketamine on postoperative pain after remifentanil infusion in patients undergoing laparoscopic gastric bypass and gastric plication surgery. Ketamine is an old general anaesthetic. Low doses of it might be used as a adjunct in postoperative analgesia.The investigators expect that the low-dose ketamine reduces postoperative pain after bariatric surgeries.

Conditions

  • Pain, Postoperative
  • Bariatric Surgery Candidate

Interventions

DRUG

Ketamine

0,15 mg/kg pre-incisional single bolus dose of ketamine in the operating room.

DRUG

Saline

Intravenous injection given pre-incisional in the operating room.

DRUG

Ketamine

0,3 mg/kg pre-incisional single bolus dose of ketamine in the operating room.

DRUG

Ketamine

0,15 mg/kg pre-incisional single bolus dose of ketamine, followed by continuous infusion of 1 mg/kg in the operating room.

DRUG

Ketamine

0,3 mg/kg (LBM) of intravenous pre-incisional single bolus injection, followed by continuous infusion of 1mg/kg ketamine given for bariatric patients in the operating room.

Sponsors & Collaborators

  • Lithuanian University of Health Sciences

    lead OTHER

Principal Investigators

  • Aurika Karbonskienė, MDPhDAssProf · Lithuanian University of Health Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-22
Primary Completion
2017-03-30
Completion
2023-06-06

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03389022 on ClinicalTrials.gov